Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Neurol Sci ; 38(11): 2007-2013, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28831591

RESUMO

Simultaneous performance of motor and cognitive tasks may compete for common brain network resources in aging or patients with some neurological diseases, suggesting the occurrence of a cognitive-motor interference. While this phenomenon has been well described for multiple sclerosis (MS) patients, it never has been tested on asymptomatic subject with magnetic resonance imaging (MRI) findings suggestive of demyelinating disease (i.e., radiologically isolated syndrome: RIS). In this pilot study, 10 RIS subjects and 10 sex/age-matched healthy controls were tested by means of static posturography under eyes opened (single-task trial) and while performing two different cognitive tasks (semantic modified word list generation for first dual-task trial and phonemic semantic modified word list generation for second dual-task trial), to estimate the dual-task cost (DTC) of standing balance. In our sample, under cognitive interference (without any substantial differences between semantic and phonemic modified word list generation), the RIS group showed significance differences in CoP (center of pressure) total sway area, ellipse eccentricity, CoP sway path length, CoP median sway velocity along the AP (anteroposterior) axis and along the ML (mediolateral) axis, reflecting a higher negative DTC respect to healthy subjects (which have simply shown a statistical trend, failing to reach a significance, in some trials). The phenomenon of cognitive-motor interference might be unmasked by a dual-task posturography in RIS subjects, too. We hypothesize that this approach could be useful to early reveal the presence of a demyelinating disease and to reach a MS diagnosis in subjects otherwise classified as RIS.


Assuntos
Cognição , Doenças Desmielinizantes/diagnóstico , Imageamento por Ressonância Magnética , Equilíbrio Postural , Adulto , Encéfalo/diagnóstico por imagem , Doenças Desmielinizantes/fisiopatologia , Doenças Desmielinizantes/psicologia , Diagnóstico Diferencial , Feminino , Humanos , Masculino , Projetos Piloto , Radiografia , Medula Espinal/diagnóstico por imagem , Adulto Jovem
2.
Pain Med ; 17(6): 1145-54, 2016 06.
Artigo em Inglês | MEDLINE | ID: mdl-26764336

RESUMO

OBJECTIVE: The aim of our study was to better investigate the role of Sativex(®) in improving pain in multiple sclerosis (MS) patients by means of either clinical or neurophysiological assessment. SETTING: Pain is a common symptom of MS, affecting up to 70% of patients. Pain treatment is often unsatisfactory, although emerging drugs (including cannabinoids) are giving encouraging results. Clinical pain assessment in MS is very difficult, and more objective tools are necessary to better quantify this symptom and its potential response to the treatments. SUBJECTS AND METHODS: We enrolled 20 MS patients (10 with and 10 without neuropathic pain), who underwent a specific clinical (such as visual analog scale) and neurophysiological assessment (by means of laser-evoked potentials and transcranial magnetic stimulation), before and after 4 weeks of Sativex administration. RESULTS: One month of drug administration in MS patients with neuropathic pain successfully reduced pain rating and improved quality of life. Interestingly, such effects were paralleled by an increase of fronto-central γ-band oscillation and of pain-motor integration strength. CONCLUSIONS: Our data suggest that Sativex may be effective in improving MS-related neuropathic pain, maybe through its action on specific cortical pathways.


Assuntos
Encéfalo/efeitos dos fármacos , Esclerose Múltipla/complicações , Neuralgia/tratamento farmacológico , Manejo da Dor/métodos , Extratos Vegetais/uso terapêutico , Adulto , Encéfalo/fisiopatologia , Canabidiol , Dronabinol , Combinação de Medicamentos , Feminino , Humanos , Potenciais Evocados por Laser , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/fisiopatologia , Neuralgia/etiologia , Medição da Dor , Estimulação Magnética Transcraniana
3.
J Sex Med ; 11(7): 1807-15, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24810799

RESUMO

INTRODUCTION: Intrathecal administration of baclofen (ITB) is widely recognized as an effective treatment for severe spasticity of both spinal and supraspinal origin with fewer side effects. The lower drug dosages used for spinal intrathecal administration, acting directly on the receptor sites, result in greater therapeutic efficacy with less systemic toxicity than with oral preparations. AIM: This study aims to prospectively evaluate the effects of ITB on erectile function in male patients affected by severe spasticity. METHODS: Twenty adult male patients, with a 34.85 ± 10.27 mean age, affected by severe spasticity mainly due to spinal cord lesions (10 traumatic, three vascular, six degenerative, and one congenital in origin) and treated with ITB, were enrolled in the study. All participants underwent specific clinical scales to evaluate force, muscle tone, cognition and mood, and specific sexual questionnaires, including an accurate semi-structured interview. MAIN OUTCOME MEASURE: The International Index of Erectile Function (IIEF) was used to evaluate sexual function before and after pump implantation. RESULTS: A comparative analysis of the neurological scales and psychometric scores at T1 (baseline) and T2 (follow-up) showed statistically significant differences before and after pump implantation. In particular, we noted a significant decrease in the IIEF median scores (from 0.42 ± 0.07 to 0.14 ± 0.02, P value < 0.0001) and a correlation between ITB dosage and IIEF scores (ρ = -0.60; P < 0.05). CONCLUSIONS: This study supports previous findings on a possible negative effect of ITB on sexual function, with regard to erection. Patients who are considering ITB for treatment of severe spasticity should be informed about possible but reversible sexual side effects, especially at higher dosage. Future studies with larger samples should be fostered to confirm these findings for a better management of these, often young, patients.


Assuntos
Baclofeno/efeitos adversos , Disfunção Erétil/induzido quimicamente , Relaxantes Musculares Centrais/efeitos adversos , Espasticidade Muscular/tratamento farmacológico , Adolescente , Adulto , Humanos , Injeções Espinhais , Masculino , Pessoa de Meia-Idade , Tono Muscular/efeitos dos fármacos , Estudos Prospectivos , Resultado do Tratamento , Adulto Jovem
4.
Funct Neurol ; 19(4): 227-31, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15776790

RESUMO

Over the past three decades, telemetric pumps have been used for the infusion of intrathecal baclofen in patients with severe spasticity, but the correlation between pump implantation and quality of life (QoL) has rarely been studied. The aim of this study was therefore to quantify QoL in these patients. We assessed 15 candidates for intrathecal baclofen infusion pump implantation using three scales: Self-Evaluation of Life Function, Quality of Life Index, and Quality of Well-Being Scale. These scales were administered a week before pump implantation and 12 months after reaching the optimal dosage. The first scale revealed a significant increase in QoL, whereas on the other two the increase was not significant. These results encourage us to continue this study in a larger patient sample, considering different types of pathology and presence/absence of caregivers.


Assuntos
Baclofeno/administração & dosagem , Bombas de Infusão Implantáveis , Relaxantes Musculares Centrais/administração & dosagem , Espasticidade Muscular/tratamento farmacológico , Espasticidade Muscular/fisiopatologia , Qualidade de Vida , Telemetria , Adulto , Idoso , Baclofeno/uso terapêutico , Doença Crônica , Avaliação da Deficiência , Feminino , Humanos , Injeções Espinhais , Masculino , Pessoa de Meia-Idade , Relaxantes Musculares Centrais/uso terapêutico , Espasticidade Muscular/psicologia , Inquéritos e Questionários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA